Clinical Trial Update: Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) [Phase 3]

View source ↗

Summary

Phase 3 long-term safety study comparing deucravacitinib with ustekinumab in adults with plaque psoriasis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Deucravacitinib (deucravacitinib)
• USTEKINUMAB (USTEKINUMAB)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Plaque Psoriasis | Phase 3 | Status: RECRUITING